ppGalNac-T10对人结直肠癌细胞株LoVo的生物学特性的影响

探讨多肽N-乙酰氨基半乳糖转移酶10(ppGalNAc-T10)对人结直肠癌细胞株LoVo细胞特性的影响.ppGalNAc-T10正义真核表达载体pcDNA3.1-T10(+)、反义真核表达载体pcDNA3.1-T10(-)与空载体pcDNA3.1分别转染LoVo细胞,Western blot检测ppGalNAc-T10蛋白水平表达的变化,确定转染效果.CCK8法检测转染后各实验组细胞增殖的变化,细胞划痕实验检测细胞迁移能力的变化,穿膜实验检测细胞侵袭能力的变化.Western blot证明各实验组经转染不同ppGalNAc-T10载体后,ppGalNAc-T10蛋白表达量发生变化,转染pp-GalNAc-T10正义真核表达载体的LoVo细胞,ppGalNAc-T10的蛋白表达量增加,同时细胞的增殖受到抑制,迁移能力和侵袭能力降低;而转染ppGalNAc-T10反义真核表达载体的LoVo细胞,ppGalNAc-T10的蛋白表达量降低,细胞生长加快,迁移能力和侵袭能力增强.ppGalNAc-T10可能影响人结直肠癌细胞株LoVo细胞的增殖、迁移能力和侵袭能力.     

蜕皮激素诱导MIIP基因的表达对肝癌细胞增殖迁移的影响

目的:探讨蜕皮激素诱导迁移侵袭抑制蛋白基因(migration and invasion inhibitory protein,MIIP)基因的表达对肝癌细胞SK-Hep-1增殖和迁移能力的影响。方法:采用PCR扩增MIIP基因,连入T载体测序正确后,插入到蜕皮激素可诱导真核表达载体pIND中。将pIND-MIIP和含蜕皮激素受体基因的表达载体pVgRXR以脂质体转染法转染到SK-Hep-1中,经G418和Zeocin双抗生素筛选获得稳定转染细胞株。蜕皮激素Ponasterone A诱导后,采用Western blot检测MIIP表达,CCK-8实验检测细胞增殖,划痕实验检测细胞迁移。结果:蜕皮激素诱导MIIP表达上调后,SK-Hep-1细胞的增殖能力显著下降(P0.05),细胞的迁移能力明显减弱。结论:建立了MIIP基因可诱导表达系统,证实在肝癌细胞SK-Hep-1中MIIP过表达可抑制细胞的增殖及迁移能力。     

LKB1抑制人巨细胞肺癌细胞的增殖和迁移侵袭、mTOR磷酸化与VEGF和MMP9表达

目的分析肝激酶B1(liver kinase B1,LKB1)对人巨细胞肺癌(the people giant cell lung cancer,PGCL3)细胞增殖、迁移、侵袭的影响及其机制。方法构建真核表达载体p CMV-LKB1,转染人巨细胞肺癌细胞。转染后48h,用免疫印迹法检测各组细胞LKB1蛋白表达水平,明确转染PGCL3效率。转染后每隔12h、连续72h检测LKB1对细胞增殖能力的影响;Transwell小室检测转染后各组细胞迁移、侵袭力。提取各组细胞蛋白检测基质金属蛋白酶2(matrix metalloproteinase 2,MMP2)、基质金属蛋白酶9(matrix metalloproteinase 9,MMP9)、雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达水平。结果 p CMV-LKB1经PCR、双酶切及DNA测序鉴定后,证实目的基因片段插入方向正确,核酸序列与NCBI公布的LKB1的核酸序列一致;免疫印迹分析显示,转染p CMV-LKB1的PGCL3细胞中LKB1表达水平明显增高,表明p CMV-LKB1构建成功。增殖曲线分析和5-乙炔基-2,脱氧嘧啶核苷(5-ethynyl-2,-deoxyuridine,Ed U)检测显示,转染p CMV-LKB1能显著抑制PGCL3细胞的增殖;Transwell小室检测显示,过表达LKB1可显著抑制PGCL3细胞的迁移与侵袭;免疫印迹分析显示,过表达LKB1的PGCL3细胞其LKB1下游分子中总m TOR表达量不变,磷酸化m TOR(p-m TOR)水平降低,m TOR下游分子VEGF表达量也显著降低,迁移侵袭相关蛋白MMP2表达无变化,但MMP9水平显著降低。结论 LKB1可能通过下调PGCL3细胞p-m TOR水平,降低VEGF表达,从而抑制巨细胞肺癌细胞增殖,并可能通过下调金属基质蛋白酶MMP9的表达,降低巨细胞肺癌细胞迁移侵袭能力。     

长链非编码RNA SPRY4-IT1对髓母细胞瘤增殖及侵袭转移的影响

目的：探讨长链非编码RNA SPRY4-IT1（LncRNA）对髓母细胞瘤增殖及侵袭转移的影响。方法：髓母细胞瘤Daoy细胞分为对照组和si-SPRY4-IT1组,分别利用脂质体Lipofectamine 2000将阴性对照荧光序列和SPRY4-IT1-siRNA转入细胞中,采用Real-time PCR检测转染后各组细胞中SPRY4-IT1的表达情况,CCK-8实验及平板克隆形成实验检测细胞增殖能力的变化,以细胞体外侵袭、迁移实验分别检测细胞侵袭、迁移能力的变化,Western blot检测SPRY4-IT1对基质金属蛋白酶（MMP）-2和MMP-9蛋白的影响。结果：si-SPRY4-IT1组SPRY4-IT1 mRNA表达水平、细胞体外增殖能力、细胞侵袭、迁移能力、细胞MMP-2蛋白表达均较对照组明显降低（P<0.05）,而MMP-9蛋白表达未见明显变化。结论：干扰长链非编码RNA SPRY4-IT1在髓母细胞瘤Daoy细胞中的表达能显著抑制细胞的增殖、侵袭和迁移能力。     

转录因子WSTF对肺癌细胞增殖和侵袭的实验研究

目的:研究转录因子WSTF对肺癌细胞增殖和侵袭作用的影响。方法:采用慢病毒介导的基因转染方法建立A549细胞WSTF高表达细胞系A549-WSTF和空质粒对照细胞系A549-control。细胞增殖实验和克隆形成实验观察ING5过表达对肺癌A549细胞增殖能力的影响;Trans-well迁移实验和侵袭实验观察WSTF对肺癌细胞迁移和侵袭能力的影响。结果:Western blot验证A549-WSTF细胞WSTF蛋白水平显著高于对照细胞A549-control,P=0.0004。WSTF高表达明显促进了肺癌细胞的增殖能力(1-4天P值分别为0.002、0.0004、0.0002和3.21×10-5)和克隆形成能力(P=0.004);WSTF过表达还显著促进了肺癌细胞从trans-well小室迁移到下室的作用,其OD570值分别为0.626±0.013(A549-WSTF)和0.322±0.010(A549-control),P=2.37×10-5;WSTF还促进肺癌细胞穿透基质胶迁移到下室,其OD570值分别为0.600±0.027(A549-WSTF)和0.333±0.017(A549-control),P=0.0004。结论:WSTF可以促进肺癌细胞的增殖和侵袭能力而发挥促癌作用。     

CDX2基因高表达对胃癌细胞生物学行为的影响

目的探讨尾侧型同源转录因子-2(CDX2)基因过表达对胃癌BGC-823细胞增殖、迁移、凋亡等生物学特征的影响。方法采用脂质体转染法建立CDX2基因过表达的胃癌BGC-823稳定细胞株,分别采用RT-PCR、Western blotting和免疫细胞化学等方法检测转染重组表达载体pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因及其蛋白的表达。MTT法检测CDX2基因过表达对细胞的增殖能力的影响;划痕实验检测CDX2过表达对细胞迁移能力的影响;流式细胞术检测CDX2过表达对细胞的凋亡的影响;应用基因芯片技术检测转染前后相关基因的差异表达。结果 RT-PCR及Western blotting检测结果显示,与对照组相比,转染pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因和蛋白均呈高表达;CDX2过表达能明显降低转然组BGC-823细胞增殖能力和迁移能力;但对细胞凋亡影响不明显;基因芯片结果提示CDX2基因高表达能影响某些基因的表达。结论 CDX2过表达能明显抑制胃癌细胞增殖、降低迁移能力,提示CDX2在胃癌中可能发挥抑癌基因的作用。     

MiRNA-509-5p靶向MDM2抑制胃癌细胞的侵袭和迁移

目的明确miRNA-509-5p对胃癌细胞侵袭和迁移的作用并阐明相关的机制。方法实时定量PCR检测miRNA-509-5p在胃癌细胞株及胃癌组织中的表达。对HGC-27细胞株转染miRNA-509-5p模拟物或抑制物后,分别采用CCK-8和Transwell法检测细胞的增殖和迁移。软件预测miRNA-509-5p的靶基因,荧光素酶报告基因验证靶基因。靶基因过表达验证细胞增殖和迁移。结果 miRNA-509-5p在肿瘤组织及细胞株中的表达显著降低。转染miRNA-509-5p模拟物能够显著抑制细胞的增殖、迁移及侵袭。相反,转染miRNA-509-5p抑制物能够显著增加细胞的增殖、迁移及侵袭。此外,miRNA-509-5p能够通过靶向3'-UTR负调控鼠双微体-2(MDM2)。miRNA-509-5p能够显著抑制由MDM2过表达导致的肿瘤细胞增殖、迁移及侵袭。结论 miRNA-509-5p是通过抑制MDM2表达的新型肿瘤抑制子,能够抑制胃癌的增殖、迁移及侵袭。     

微小RNA-451a对胰腺癌BxPc3细胞增殖、侵袭及迁移的影响

摘要 目的：研究微小RNA（miR）-451a对胰腺癌BxPc3细胞增殖、侵袭和迁移的影响。方法：体外培养BxPc3细胞,将不同浓度（50、100 和 200 μmol/L）miR-451a模拟物（mimic）转染至胰腺癌细胞株BxPc3中,利用荧光定量聚合酶链式反应（ PCR）法检测miR-451a的表达,MTT增殖实验检测不同浓度miR-451a对细胞增殖的影响,细胞划痕实验检测不同浓度miR-451a对细胞迁移能力的影响,Transwell实验检测不同浓度miR-451a对细胞侵袭能力的影响。Western blot法检测不同浓度 miR-451a转染后BxPc3细胞p-PI3K、p-AKT、TGF-β和p-smad2/3 蛋白的表达情况。结果：转染不同浓度miR-451a mimic后,胰腺癌BxPc3细胞内miR-451a的相对表达量明显升高,差异有统计学意义（P<0.05）。过表达miR-451a后,BxPc3细胞的增殖能力明显减弱,细胞迁移能力明显减弱,细胞侵袭能力明显减弱,差异均有统计学意义（P<0.05）。相比于0 μmol/L 组,转染50、200 μmol/L miR-451a后BxPc3 细胞p-PI3K、p-AKT、TGF-β和p-smad2/3蛋白表达水平明显降低（P<0.05）,并且p-PI3K、p-AKT、TGF-β和p-smad2/3蛋白表达水平变化具有浓度依耐性。结论：miR-451a能抑制胰腺癌BxPc3细胞株的增殖、迁移、侵袭能力。     

人β防御素-2通过TGF-β/Smad信号通路对胃癌SGC7901细胞增殖、迁移和侵袭的影响

该文探讨了人β防御素-2(hBD2)对胃癌SGC7901细胞的增殖、迁移和侵袭的影响。将真核表达载体pCMV-hBD2转染于人胃癌SGC7901细胞。采用qPCR和免疫印迹法(Western blot)检测转染效率。Western blot检测TGF-β1、p-Smad2/3、Smad2/3、MMP9的蛋白表达水平。Transwell法检测SGC7901细胞迁移和侵袭能力。EdU法和流式细胞术分别检测增殖能力与细胞周期。结果显示,转染真核表达载体pCMV-hBD2的SGC7901细胞, hBD2的表达水平明显高于SGC7901和转染pCMV-Blank的SGC7901细胞。SGC7901-hBD2细胞中TGF-β1、p-Smad2/3和MMP9的蛋白表达水平均低于SGC7901和SGC7901-Blank细胞,而Smad2/3表达水平不变。同时,其迁移侵袭和增殖能力均受到抑制,细胞周期G0/G1期阻滞。该实验结果表明, hBD2可能通过下调TGF-β/Smad信号通路调控SGC7901细胞的迁移侵袭以及增殖能力。     

上调OPN和TIP30表达对口腔鳞癌cal-27细胞的影响

目的:探讨上调骨桥蛋白(OPN)和TIP30表达对口腔鳞状细胞癌cal-27细胞增殖和迁移能力的影响。方法:采用过表达OPN载体病毒和过表达TIP30质粒分别感染或转染cal-27细胞株后,通过实时荧光定量PCR法和蛋白印迹western blot法检测OPN和TIP30的表达,CCK-8法检测细胞增殖能力,细胞划痕实验检测细胞的迁移能力。结果:过表达OPN载体病毒感染的cal-27-sh OPN细胞株OPN m RNA和蛋白的表达均明显高于cal-27-sh N细胞株(P0.001,P=0.002),且细胞的增殖能力和迁移能力强(P0.001,P=0.002)。过表达TIP30质粒转染的cal-27-p TIP30细胞株TIP30 m RNA和蛋白的表达均明显高于cal-27-pc3.0细胞株(P=0.001,P=0.003),且细胞的增殖能力和迁移能力弱(P0.001,P=0.005)。结论:OPN能促进cal-27细胞的增殖和迁移,TIP30抑制cal-27细胞的增殖和迁移。     

TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways

The pathogenesis of lung cancer, the most common cancer, is complex and unclear, leading to limited treatment options and poor prognosis. To provide molecular insights into lung cancer development, we investigated the function and underlying mechanism of SH2B3 in the regulation of lung cancer. We indicated SH2B3 was diminished while TGF-β1 was elevated in lung cancer tissues and cells. Low SH2B3 level was correlated with poor prognosis of lung cancer patients. SH2B3 overexpression suppressed cancer cell anoikis resistance, proliferation, migration, invasion, and EMT, while TGF-β1 promoted those processes via reducing SH2B3. SH2B3 bound to JAK2 and SHP2 to repress JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling pathways, respectively, resulting in reduced cancer cell anoikis resistance, proliferation, migration, invasion, and EMT. Overexpression of SH2B3 suppressed lung cancer growth and metastasis in vivo. In conclusion, SH2B3 restrained the development of anoikis resistance and EMT of lung cancer cells via suppressing JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling cascades, leading to decreased cancer cell proliferation, migration, and invasion. Subject terms: Cell migration, Lung cancer     

Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity

The mammalian target of rapamycin (mTOR) regulates the motility and invasion of cancer cells. Cardamonin is a chalcone that exhibits anti-tumor activity. The previous study had proved that the anti-tumor effect of cardamonin was associated with mTOR inhibition. In the present study, the anti-metastatic effect of cardamonin and its underlying molecule mechanisms were investigated on the highly metastatic Lewis lung carcinoma (LLC) cells. The proliferation, invasion and migration of LLC cells were measured by MTT, transwell and wound healing assays, respectively. The expression and activation of mTOR- and adhesion-related proteins were assessed by Western blotting. The in vivo effect of cardamonin on the metastasis of the LLC cells was investigated by a mouse model. Treated with cardamonin, the proliferation, invasion and migration of LLC cells were significantly inhibited. The expression of Snail was decreased by cardamonin, while that of E-cadherin was increased. In addition, cardamonin inhibited the activation of mTOR and its downstream target ribosomal S6 kinase 1 (S6K1). Furthermore, the tumor growth and its lung metastasis were inhibited by cardamonin in C57BL/6 mice. It indicated that cardamonin inhibited the invasion and metastasis of LLC cells through inhibiting mTOR. The metastasis inhibitory effect of cardamonin was correlated with down-regulation of Snail and up-regulation of E-cadherin.     

盐酸罗哌卡因对骨肉瘤细胞增殖、侵袭、凋亡的影响及其机制*

目的:探讨盐酸罗哌卡因对骨肉瘤细胞增殖、侵袭、凋亡的影响及分子机制。方法:采用逐步增加药物剂量诱导法建立骨肉瘤多柔比星耐药细胞株(U2OS/DOX),用浓度分别为0、20、50、100 μg/ml的盐酸罗哌卡因处理U2OS/DOX细胞,作为不同浓度盐酸罗哌卡因处理组;将pcDNA3.1、pcDNA3.1-Livin转染至U2OS/DOX细胞中再用浓度为100 μg/ml的盐酸罗哌卡因处理,记为盐酸罗哌卡因100 μg/ml+pcDNA3.1组、盐酸罗哌卡因100 μg/ml+pcDNA3.1-Livin组。MTT检测细胞增殖抑制率及细胞半数抑制浓度(IC₅₀);蛋白质印迹(Western blot)法检测细胞周期蛋白依赖性激酶抑制剂1A(P21)、活化的半胱氨酸天冬氨酸蛋白酶-3(Cleaved Caspase-3)、上皮钙黏蛋白(E-cadherin)、基质金属蛋白酶2(MMP-2)、Livin蛋白表达;克隆形成实验检测细胞克隆形成数;流式细胞术检测细胞凋亡;Transwell检测细胞迁移和侵袭;实时荧光定量PCR(RT-qPCR)检测Livin mRNA表达水平。结果:多柔比星浓度大于1 μg/ml时,骨肉瘤细胞U2OS增殖抑制率显著升高,且具有剂量依赖性(P＜0.05);多柔比星浓度大于10 μg/ml时,骨肉瘤细胞骨肉瘤耐药细胞U2OS/DOX增殖抑制率显著升高,且具有剂量依赖性(P＜0.05)。盐酸罗哌卡因处理的U2OS/DOX细胞中P21、Caspase-3、E-cadherin表达水平显著升高,MMP-2表达水平显著降低,细胞增殖抑制率显著升高,克隆形成数显著降低,细胞凋亡率显著升高,细胞迁移、侵袭数显著降低,Livin表达水平显著降低,且呈浓度依赖性(P＜0.05)。过表达Livin部分逆转了盐酸罗哌卡因对细胞U2OS/DOX增殖、迁移、侵袭的抑制作用及凋亡的促进作用。结论:盐酸罗哌卡因能明显抑制对多柔比星具有耐药性的骨肉瘤细胞的增殖,迁移和侵袭,明显促进骨瘤细胞凋亡,其机制可能与Livin有关。     

甘草提取物通过调控miR-212-5p/BCL2L2 基因抑制甲状腺肿瘤细胞的增殖、迁移和侵袭

目的探讨甘草提取物GL-1对甲状腺肿瘤细胞增殖、迁移和侵袭的影响及其分子机制。方法以10、20、30 μg/mL GL-1处理甲状腺肿瘤细胞CAL-62,或在CAL-62细胞中转染miR-212-5p mimics、anti-miR-212-5p、si-BCL2L2、pcDNA-BCL2L2。其中转染pcDNA-BCL2L2细胞并以30 μg/mL GL-1处理。噻唑蓝比色法 (MTT)检测CAL-62细胞增殖,Transwell小室法检测CAL-62细胞迁移和侵袭,实时定量PCR (qPCR)检测CAL-62细胞中miR-212-5p表达,Western blot检测相关蛋白Bcl-2样蛋白2 (BCL2L2)、细胞周期蛋白D1 (Cyclin D1)和基质金属蛋白酶-2 (MMP-2)表达。生物学信息预测miR-212-5p的下游靶基因,双荧光素酶基因报告实验进一步验证。数据采用单因素方差分析、Tukey’s事后检验和t检验。结果与对照组相比,10、20、30 μg/mL浓度GL-1降低CAL-62细胞24、48、72 h的细胞活性 (P < 0.05),并呈剂量、时间依赖性。与对照组相比,10、20、30 μg/mL浓度GL-1干预后,CAL-62细胞侵袭数[(143.56±14.22)个、(100.32±10.23)个、(68.23±6.49)个比(189.65±15.23)个]、迁移数[(198.56±14.35)个、(141.35±12.58)个、(89.56±8.95)个比 (295.36±17.56)个]和BCL2L2蛋白表达量 (0.76±0.08、0.51±0.06、0.24±0.02比1.00±0.12)均降低 (P 均< 0.05),而miR-212-5p水平 (1.61±0.11、1.99±0.13、2.28±0.15比1.00±0.07)升高(P < 0.05),并呈剂量依赖性。过表达miR-212-5p和沉默BCL2L2表达在24、48、72 h时CAL-62细胞活性、细胞迁移数、侵袭数和Cyclin D1、MMP-2蛋白表达量降低 (P < 0.05)。生物学信息预测和双荧光素酶基因报告实验证实BCL2L2是miR-212-5p的靶基因。过表达miR-212-5p抑制BCL2L2蛋白水平,沉默miR-212-5p促进BCL2L2蛋白表达 (P < 0.05)。过表达BCL2L2可逆转GL-1对CAL-62细胞增殖、迁移、侵袭及Cyclin D1、MMP-2蛋白表达的抑制作用。结论 GL-1通过miR-212-5p/BCL2L2抑制甲状腺肿瘤细胞的增殖、迁移和侵袭。     

Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk

The beta-chemokine receptor CCR5 has been shown to modulate cell migration, proliferation, and immune functions and to serve as a co-receptor for the human immunodeficiency virus. We and others have shown that CCR5 activates related adhesion focal tyrosine kinase (RAFTK)/Pyk2/CAK-beta. In this study, we further characterize the signaling molecules activated by CCR5 upon binding to its cognate ligand, macrophage inflammatory protein-1beta (MIP1beta). We observed enhanced tyrosine phosphorylation of the phosphatases SHP1 and SHP2 upon MIP1beta stimulation of CCR5 L1.2 transfectants and T-cells derived from peripheral blood mononuclear cells. Furthermore, we observed that SHP1 associated with RAFTK. However, using a dominant-negative phosphatase-binding mutant of RAFTK (RAFTK(m906)), we found that RAFTK does not mediate SHP1 or SHP2 phosphorylation. SHP1 and SHP2 also associated with the adaptor protein Grb2 and the Src-related kinase Syk. Pretreatment of CCR5 L1.2 transfectants or T-cells with the phosphatase inhibitor orthovanadate markedly abolished MIP1beta-induced chemotaxis. Syk was also activated upon MIP1beta stimulation of CCR5 L1.2 transfectants or T-cells and associated with RAFTK. Overexpression of a dominant-negative Src-binding mutant of RAFTK (RAFTK(m402)) significantly attenuated Syk activation, whereas overexpression of wild-type RAFTK enhanced Syk activity, indicating that RAFTK acts upstream of CCR5-mediated Syk activation. Taken together, these results suggest that MIP1beta stimulation mediated by CCR5 induces the formation of a signaling complex consisting of RAFTK, Syk, SHP1, and Grb2.     

SB-431542抑制乳腺癌细胞BT-549的增殖和侵袭及其机理研究

肿瘤转移是导致肿瘤患者死亡的最主要原因,TGF-β超家族成员Nodal分子被证实参与肿瘤细胞的增殖和转移,因而基于Nodal信号为靶标开展抗肿瘤研究成为可能。该研究应用Western blot检测乳腺癌细胞株BT-549、T-47D、MCF-7、SK-BR-3和MDA—MB-231中的Nodal和基质金属蛋白酶-2（matrix metalloproteinase-2,MMP-2）的表达水平,发现它们在BT-549细胞中表达量最高。然后采用不同浓度_Nodal信号抑制剂SB．431542（1-50μmol／L）处理BT-549细胞48h,利用MTT法揭示20～50gmol／L的SB-431542抑制该细胞增殖。进一步利用细胞划痕和Transwell实验证明,10μmol／L的SB-431542可抑制乳腺癌细胞的迁移和侵袭。最后,通过明胶酶谱和Westernblot显示,10～30gmol／L的sB．431542可剂量依赖性地抑制MMP-2的表达和活性。上述结果说明,SB-431542通过阻断Nodal信号通路可效抑制乳腺癌细胞BT-549的增殖、迁移和侵袭,其作用机制可能与降低MMP-2的表达和活性有关。     

miRNA-1和miRNA-133过表达对L6细胞增殖与分化的影响

目的观察大鼠微小RNA-1（miR-1）、微小RNA-133（miR-133）过表达对L6成肌细胞增殖分化的影响。方法分别构建miR-1、miR-133的重组慢病毒载体,并进行测序鉴定,稳定转染L6细胞后,用RT-PCR Taqman探针的方法检测miR-1、miR-133的表达水平;细胞计数实验（CCK-8试剂盒）评价miR-1、miR-133过表达后对L6细胞增殖的影响。诱导稳定转染后L6成肌细胞进行分化,观察miR-1、miR-133过表达后对L6细胞分化的影响。以Western blot法检测miR-1、miR-133过表达后,α肌动蛋白（skeletalα-actin）表达水平的变化。采用Kruskal-Wallis H检验、重复测量和单因素方差分析进行比较。结果miR-1慢病毒载体经酶切和测序鉴定序列准确,转染48 h后L6细胞miR-1组（4.292±0.50）比control组（0.231±0.86）、miR-133组（0.205±0.48）比control组（3.564±0.45）表达均显著上调（P〈0.001）;细胞计数和细胞分化实验显示,培养120 h后,过表达miR-1的L6细胞α肌动蛋白（skeletalα-actin）比对照组（0.415±0.02）表达显著升（0.676±0.02,F=222.144,P〈0.001）,分化明显加快,但增殖无明显变化;而过表达miR-133的L6细胞增殖明显加快,α肌动蛋白表达呈下降趋势（0.363±0.02,F=2385.643,P〈0.001）,分化受到抑制。结论 miR-1、miR-133慢病毒表达载体稳定转染L6成肌细胞后高效表达miR-1和miR-133,miR-1可促进L6细胞分化,miR-133能促进L6细胞增殖但抑制其分化。     

长链非编码RNA LINC00885在人食管癌细胞中的作用研究

探讨长链非编码RNA LINC00885对人食管癌细胞EC109增殖、迁移与侵袭的影响。构建LINC00885基因过表达质粒（pcDNA3.1-LINC00885）和shRNA敲低质粒（pLKO.1-LINC00885）。分别采用集落形成实验检测EC109细胞增殖能力;划痕实验检测EC109细胞横向迁移能力;Transwell实验检测EC109细胞纵向迁移能力及侵袭能力;流式实验检测LINC00885对于细胞周期的调控;实时定量PCR方法检测LINC00885 mRNA转录水平;Western blot检测BMP7及上皮间充质转化（epithelial-to-mesenchymal transition,EMT）通路相关蛋白（VIMENTIN、β-catenim和ZO-1）表达水平。在过表达LINC00885的EC109细胞中,细胞的增殖能力、迁移能力及侵袭能力均显著增强,BMP7蛋白表达升高;而在敲低表达LINC00885的EC109细胞中,细胞的增殖能力、迁移能力与侵袭能力均显著降低,BMP7蛋白表达也随之降低。另外,在过表达LINC00885的EC109细胞中,EMT通路蛋白VIMENTIN、β-catenim表达水平显著升高,而ZO-1表达水平显著降低。通过探究LINC00885对食管癌细胞增殖、迁移能力的影响,旨在验证LINC00885在食管癌中的功能,以期为临床治疗食管癌奠定理论基础。     

RASAL1 influences the proliferation and invasion of gastric cancer cells by regulating the RAS/ERK signaling pathway

The aim of this study was to investigate the biological characteristics of the RASAL1 gene in a well-differentiated gastric cancer cell line MKN-28 and a poorly differentiated gastric cancer cell line BGC-823 cells, using RNA interference and gene transfection technology, respectively. MKN-28 cells were transfected with the shRNA of RASAL1 and BGC-823 cells were transfected with the pcDNA 3.1 plasmid vector containing RASAL1. RT-PCR and western blotting were then used to detect the expression of RASAL1 mRNA and protein. The activities of RAS and extracellular signal-regulated kinase 1/2 were analyzed by the pull-down method and western blotting. The proliferate capacity, apoptosis rate, invasive and migratory potentials of MKN-28 or BGC-823 cells were also measured by Cell Counting Kit-8 cell proliferation assay, propidium iodide/Annexin V staining coupled with flow cytometry, and transwell chamber assays, respectively. Measurement of RASAL1 mRNA and protein expression in two cells revealed successful transfection of the shRNA of RASAL1 and RASAL1-pcDNA3.1 plasmid into these two cells. Moreover, decreased expression of RASAL1 in MKN-28 cells resulted in increased expression of RAS-GTP and p-ERK1/2. Interestingly, decreased expression of RASAL1 inhibited apoptosis and facilitated cell proliferation, invasion and migration. The increased expression of RASAL1 in BGC-823 cells caused declined expression of RAS-GTP and p-ERK1/2, as well as promoted apoptosis and restrained cell proliferation, invasion and migration. The down-regulation of RASAL1 promoted the proliferation, invasion and migration of gastric cancer MKN-28 cells, and up-regulation of RASAL1 inhibited the proliferation, invasion and migration of BGC-823 gastric cancer cells by regulating the RAS/ERK signaling pathway. Thus, our results suggest that RASAL1 may play an important role as a tumor suppressor gene in gastric cancer.